• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Perceptive Advisors Llc bought $29,999,522 worth of shares (2,481,350 units at $12.09) (SEC Form 4)

    2/5/24 5:02:33 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATXS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    PERCEPTIVE ADVISORS LLC

    (Last) (First) (Middle)
    51 ASTOR PLACE, 10TH FLOOR

    (Street)
    NEW YORK NY 10003

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Astria Therapeutics, Inc. [ ATXS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    02/01/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/01/2024 P 2,481,350 A $12.09 4,873,721 I See footnote(1)
    Common Stock 1,611,699 I See footnote(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    PERCEPTIVE ADVISORS LLC

    (Last) (First) (Middle)
    51 ASTOR PLACE, 10TH FLOOR

    (Street)
    NEW YORK NY 10003

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

    (Last) (First) (Middle)
    51 ASTOR PLACE, 10TH FLOOR

    (Street)
    NEW YORK NY 10003

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Perceptive Xontogeny Venture Fund, LP

    (Last) (First) (Middle)
    51 ASTOR PLACE, 10TH FLOOR

    (Street)
    NEW YORK NY 10003

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    EDELMAN JOSEPH

    (Last) (First) (Middle)
    51 ASTOR PLACE, 10TH FLOOR

    (Street)
    NEW YORK NY 10003

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the :Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
    2. The securities are directly held by Perceptive Xontogeny Ventures, L.P. ("PXV"). The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
    /s/ Joseph Edelman - for Perceptive Advisors LLC, By: Joseph Edelman, its managing member 02/05/2024
    /s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd, By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member 02/05/2024
    /s/ Joseph Edelman - for Perceptive Xontogeny Venture Fund L.P., By: Perceptive Xontogeny Ventures GP, LLC, its general partner, By: Joseph Edelman, its managing member 02/05/2024
    /s/ Joseph Edelman 02/05/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ATXS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATXS

    DatePrice TargetRatingAnalyst
    4/29/2025$47.00Overweight
    Cantor Fitzgerald
    1/31/2025$26.00Mkt Outperform
    JMP Securities
    7/29/2024$35.00Buy
    TD Cowen
    3/28/2023$18.00Outperform
    Evercore ISI
    9/29/2021$20.00Buy
    Jefferies
    More analyst ratings

    $ATXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CEO and President Milne Jill C.

      4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

      3/25/25 4:07:38 PM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Business Officer Matthews Andrea

      4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

      3/25/25 4:07:11 PM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Komjathy Andrew

      4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

      3/25/25 4:06:49 PM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Astria Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Astria Therapeutics with a rating of Overweight and set a new price target of $47.00

      4/29/25 8:10:45 AM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on Astria Therapeutics with a new price target

      JMP Securities initiated coverage of Astria Therapeutics with a rating of Mkt Outperform and set a new price target of $26.00

      1/31/25 6:57:00 AM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Astria Therapeutics with a new price target

      TD Cowen initiated coverage of Astria Therapeutics with a rating of Buy and set a new price target of $35.00

      7/29/24 7:30:39 AM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATXS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Astria Therapeutics Inc.

      10-Q - Astria Therapeutics, Inc. (0001454789) (Filer)

      5/13/25 4:01:39 PM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Astria Therapeutics Inc.

      SCHEDULE 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

      5/12/25 10:10:16 AM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Astria Therapeutics Inc.

      DEFA14A - Astria Therapeutics, Inc. (0001454789) (Filer)

      4/28/25 4:06:18 PM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Astria Therapeutics Inc.

      SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

      11/14/24 5:46:12 PM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Astria Therapeutics Inc.

      SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

      11/14/24 5:45:56 PM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Astria Therapeutics Inc.

      SC 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)

      11/14/24 4:41:28 PM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATXS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress

      Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four posters at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, taking place June 13-16, 2025 in Glasgow, United Kingdom. Dr. William Yang, M.D., FRCPC, FAAAAI, Managing Director and Chair, Ottawa Allergy Research Corporation, will present combined initial safety and efficacy data from the Phase 1b/2 and long-term open label trials of navenibart in a late-breaking poster presentation of poster number D1.390 titled, "Long-term Safety and Efficacy of Navenibart in Parti

      6/6/25 8:00:00 AM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 62,000 shares of Astria's common stock on June 2, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted as an inducement material to two employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $4.78, which is equal to the closing price of Astria'

      6/3/25 4:10:00 PM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference

      Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference on Wednesday, June 4th at 1:25pm ET. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff319/atxs/1878784. An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event. About Astria Therapeutics: Astria Therapeutics is a biopharmaceutical company, and our mission

      5/28/25 8:00:00 AM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATXS
    Leadership Updates

    Live Leadership Updates

    See more
    • Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors

      Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors. Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience. "It is a pleasure to welcome Sunil to our Board of Directors," said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. "His extensive drug development and clinical expertise strongly complements our Board's skills and experiences, and we look forward to his contributions as we continue to advance our programs into later-stage cl

      4/9/24 8:00:00 AM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Perceptive Advisors Llc bought $29,999,522 worth of shares (2,481,350 units at $12.09) (SEC Form 4)

      4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

      2/5/24 5:02:33 PM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perceptive Advisors Llc bought $4,588,000 worth of shares (740,000 units at $6.20) (SEC Form 4)

      4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

      12/22/23 2:51:57 PM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perceptive Advisors Llc bought $6,999,997 worth of shares (1,074,608 units at $6.51) (SEC Form 4)

      4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

      10/18/23 4:11:36 PM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATXS
    Financials

    Live finance-specific insights

    See more
    • Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE

      -- STAR-0215 Dosed Once or Twice Over 6 Months Reduced Monthly Attack Rates by 90-96%, Supporting Chronic Dosing 2 or 4 Times Per Year -- -- 92-100% Decrease in Moderate or Severe Attacks and 91-95% Reduction in Attacks Requiring Rescue Medications with STAR-0215 -- -- Very Well-Tolerated with No Serious Adverse Events and No Discontinuations -- -- Phase 3 Initiation on Track for Q1 2025, with Top-Line Results Expected by Year End 2026 -- -- Current Cash Expected to Fund Company into Mid-2027 -- -- Conference Call Today at 8:30am ET – Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological

      3/25/24 7:30:00 AM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Astria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13th

      Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, will report third quarter 2023 financial results before the Nasdaq Global Market open on Monday, November 13, 2023. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss third quarter financial results. Webcast Information: Interested parties may join the webcast via the Investors section of the Astria website, www.astriatx.com, or with the following link: https://lifescievents.com/event/astria-2/. Please connect to the webca

      10/30/23 8:00:00 AM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio

      -- Differentiated Preclinical Lead Candidate STAR-0310 to be Developed as a Potential Best-in-Class Long-Acting Treatment for Atopic Dermatitis – -- Conference Call and Webcast to be Held on October 12, 2023 at 8:30am ET -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has entered into a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the potential treatment of atopic dermatitis (AD) and potentially for other allergic and immunological diseases. Astria plans to develop the lead candidate, called STAR-03

      10/11/23 5:10:00 PM ET
      $ATXS
      Biotechnology: Pharmaceutical Preparations
      Health Care